FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Anaesth Analg / Use of a soluble epoxide hydrolase inhibitor as an adjunctiv...
Veterinary anaesthesia and analgesia2013; 40(4); 440-448; doi: 10.1111/vaa.12030

Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis.

Abstract: A 4-year old, 500 kg Thoroughbred female horse diagnosed with bilateral forelimb laminitis and cellulitis on the left forelimb became severely painful and refractory to non-steroidal anti-inflammatory therapy (flunixin meglumine on days 1, 2, 3 and 4; and phenylbutazone on days 5, 6 and 7) alone or in combination with gabapentin (days 6 and 7). Methods: Pain scores assessed independently by three individuals with a visual analog scale (VAS; 0 = no pain and 10 = worst possible pain) were 8.5 on day 6, and it increased to 9.5 on day 7. Non-invasive blood pressure monitoring revealed severe hypertension. Results: As euthanasia was being considered for humane reasons, a decision was made to add an experimental new drug, trans-4-{4-[3-(4-Trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB), which is a soluble epoxide hydrolase (sEH) inhibitor, to the treatment protocol. Dose and frequency of administration were selected based on the drug potency against equine sEH to produce plasma concentrations within the range of 30 nmol L(-1) and 2.5 μmol L(-1) . Pain scores decreased sharply and remarkably following t-TUCB administration and blood pressure progressively decreased to physiologic normal values. Plasma concentrations of t-TUCB, measured daily, were within the expected range, whereas phenylbutazone and gabapentin plasma levels were below the suggested efficacious concentrations. Results: No adverse effects were detected on clinical and laboratory examinations during and after t-TUCB administration. No new episodes of laminitis have been noted up to the time of writing (120 days following treatment). Conclusions: Inhibition of sEH with t-TUCB was associated with a significant improvement in pain scores in one horse with laminitis whose pain was refractory to the standard of care therapy. No adverse effects were noticed. Future studies evaluating the analgesic and protective effects of these compounds in painful inflammatory diseases in animals are warranted.
© 2013 The Authors. Veterinary Anaesthesia and Analgesia © 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia.
Get Full Text
Publication Date: 2013-03-07 PubMed ID: 23463912PubMed Central: PMC3956586DOI: 10.1111/vaa.12030Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Case Reports
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper investigates the effects of an experimental drug (t-TUCB), a soluble epoxide hydrolase (sEH) inhibitor, in managing pain in a horse suffering from laminitis and cellulitis. The study reports significant improvements in pain scores with no observable side effects.

Research Description

The study focuses on a four-year-old, Thoroughbred female horse weighing 500 kg. The horse had been diagnosed with bilateral forelimb laminitis and cellulitis on its left forelimb, leading to severe pain. Despite administering non-steroidal anti-inflammatory therapy (flunixin meglumine on days 1, 2, 3, and 4, and phenylbutazone on days 5, 6, and 7) either on its own or in combination with gabapentin (days 6 and 7), the horse’s condition did not improve. The horse’s pain scores only increased, as assessed by three separate individuals using a visual analog scale (VAS), moving from 8.5 on day 6 to 9.5 on day 7.

Research Methodology

  • As the horse’s situation deteriorated, researchers decided to introduce an experimental new drug, trans-4-{4-[3-(4-Trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB), a sEH inhibitor, to the treatment protocol.
  • The dose and frequency of administration were determined based on the drug’s potency against equine sEH to produce plasma concentrations within the range of 30 nmol L(-1) and 2.5 μmol L(-1).
  • Non-invasive blood pressure monitoring documented severe hypertension pre-treatment. The horse’s pain scores and blood pressure were tracked daily.

Results

  • Following the administration of t-TUCB, the horse’s pain scores significantly reduced and its blood pressure decreased to normal levels. The daily plasma concentrations of t-TUCB were within the expected range, while levels of phenylbutazone and gabapentin were below the efficacious concentrations.
  • No adverse side effects from t-TUCB were observed during clinical or laboratory exams. More than 120 days after treatment, no new episodes of laminitis were recorded.

Conclusions

The introduction of t-TUCB as an additive treatment greatly improved the horse’s condition. The sEH inhibitor noticeably reduced pain and normalized blood pressure in the horse. Furthermore, there were no notable negative side effects of the drug. This study suggests the need for future studies to further investigate the analgesic and protective effects of such compounds in treating painful inflammatory diseases in animals.

Cite This Article

APA
Guedes AG, Morisseau C, Sole A, Soares JH, Ulu A, Dong H, Hammock BD. (2013). Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. Vet Anaesth Analg, 40(4), 440-448. https://doi.org/10.1111/vaa.12030

Publication

Veterinary anaesthesia and analgesia
ISSN: 1467-2995
NlmUniqueID: 100956422
Country: United States
Language: English
Volume: 40
Issue: 4
Pages: 440-448

Researcher Affiliations

Guedes, Alonso G P
  • Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA. aguedes@ucdavis.edu
Morisseau, Christophe
    Sole, Albert
      Soares, Joao H N
        Ulu, Arzu
          Dong, Hua
            Hammock, Bruce D

              MeSH Terms

              • Analgesics / administration & dosage
              • Analgesics / pharmacology
              • Animals
              • Benzoates / therapeutic use
              • Epoxide Hydrolases / antagonists & inhibitors
              • Female
              • Foot Diseases / drug therapy
              • Foot Diseases / veterinary
              • Hoof and Claw
              • Horse Diseases / drug therapy
              • Horses
              • Inflammation / drug therapy
              • Inflammation / veterinary
              • Pain / drug therapy
              • Phenylurea Compounds / therapeutic use

              Grant Funding

              • ES02710 / NIEHS NIH HHS
              • R01 ES002710 / NIEHS NIH HHS
              • P42 ES004699 / NIEHS NIH HHS
              • P42 ES04699 / NIEHS NIH HHS
              • R37 ES002710 / NIEHS NIH HHS

              References

              This article includes 42 references
              1. Belknap JK, Giguere S, Pettigrew A. Lamellar pro-inflammatory cytokine expression patterns in laminitis at the developmental stage and at the onset of lameness: innate vs. adaptive immune response.. Equine Vet J 2007;39:42–47.
                pubmed: 17228594
              2. Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.. Pharmacol Res 2005;52:302–306.
                pubmed: 15939622
              3. Chiamvimonvat N, Ho CM, Tsai HJ. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.. J Cardiovasc Pharmacol 2007;50:225–237.
                pubmed: 17878749
              4. Davis JL, Posner LP, Elce Y. Gabapentin for the treatment of neuropathic pain in a pregnant horse.. J Am Vet Med Assoc 2007;231:755–758.
                pubmed: 17764439
              5. Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling.. Arch Toxicol 2009;83:297–318.
                pubmed: 19340413
              6. Driessen B, Bauquier SH, Zarucco L. Neuropathic pain management in chronic laminitis.. Vet Clin North Am Equine Pract 2010;26:315–337.
                pubmed: 20699178
              7. Eckhardt K, Ammon S, Hofmann U. Gabapentin enhances the analgesic effect of morphine in healthy volunteers.. Anesth Analg 2000;91:185–191.
                pubmed: 10866910
              8. Hood DM. The pathophysiology of developmental and acute laminitis.. Vet Clin North Am Equine Pract 1999;15:321–343.
                pubmed: 10472115
              9. Hood DM, Grosenbaugh DA, Mostafa MB. The role of vascular mechanisms in the development of acute equine laminitis.. J Vet Intern Med 1993;7:228–234.
                pubmed: 8246212
              10. Hwang SH, Tsai HJ, Liu JY. Orally bioavailable potent soluble epoxide hydrolase inhibitors.. J Med Chem 2007;50:3825–3840.
                pmc: PMC2596069pubmed: 17616115
              11. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.. Nat Rev Drug Discov 2009;8:794–805.
                pmc: PMC3021468pubmed: 19794443
              12. Inceoglu B, Jinks SL, Schmelzer KR. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.. Life Sci 2006;79:2311–2319.
                pmc: PMC1904345pubmed: 16962614
              13. Inceoglu B, Jinks SL, Ulu A. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways.. Proc Natl Acad Sci U S A 2008;105:18901–18906.
                pmc: PMC2596245pubmed: 19028872
              14. Inceoglu B, Schmelzer KR, Morisseau C. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007;82:42–49.
                pmc: PMC1904338pubmed: 17164131
              15. Inceoglu B, Wagner K, Schebb NH. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP.. Proc Natl Acad Sci U S A 2011;108:5093–5097.
                pmc: PMC3064364pubmed: 21383170
              16. Jones E, Vinuela-Fernandez I, Eager RA. Neuropathic changes in equine laminitis pain.. Pain 2007;132:321–331.
                pubmed: 17935886
              17. Lakritz J, Winder BS, Noorouz-Zadeh J. Hepatic and pulmonary enzyme activities in horses.. Am J Vet Res 2000;61:152–157.
                pubmed: 10685686
              18. Liu J, Feng X, Yu M. Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain.. Neurosci Lett 2007;412:268–272.
                pubmed: 17140731
              19. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain.. Brain Res Rev 2006;51:240–264.
                pubmed: 16388853
              20. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles.. Annu Rev Pharmacol Toxicol 2005;45:311–333.
                pubmed: 15822179
              21. Morisseau C, Hammock BD. Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical.. Pest Manag Sci 2008;64:594–609.
                pubmed: 18383502
              22. Morisseau C, Inceoglu B, Schmelzer K. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.. J Lipid Res 2010;51:3481–3490.
                pmc: PMC2975720pubmed: 20664072
              23. Morisseau C, Newman JW, Tsai HJ. Peptidyl-urea based inhibitors of soluble epoxide hydrolases.. Bioorg Med Chem Lett 2006;16:5439–5444.
                pmc: PMC1892215pubmed: 16908134
              24. Murakami M. Lipid mediators in life science.. Exp Anim 2011;60:7–20.
                pubmed: 21325748
              25. Node K, Huo Y, Ruan X. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.. Science 1999;285:1276–1279.
                pmc: PMC2720027pubmed: 10455056
              26. Parks A, O’Grady SE. Chronic laminitis: current treatment strategies.. Vet Clin North Am Equine Pract 2003;19:393–416.
                pubmed: 14575166
              27. Peroni JF, Moore JN, Noschka E. Predisposition for venoconstriction in the equine laminar dermis: implications in equine laminitis.. J Appl Physiol 2006;100:759–763.
                pubmed: 16269525
              28. Revermann M. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.. Curr Opin Pharmacol 2010;10:173–178.
                pubmed: 20079692
              29. Schmelzer KR, Inceoglu B, Kubala L. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors.. Proc Natl Acad Sci U S A 2006;103:13646–13651.
                pmc: PMC1564210pubmed: 16950874
              30. Schmelzer KR, Kubala L, Newman JW. Soluble epoxide hydrolase is a therapeutic target for acute inflammation.. Proc Natl Acad Sci U S A 2005;102:9772–9777.
                pmc: PMC1168955pubmed: 15994227
              31. Sumano Lopez H, Hoyas Sepulveda ML, Brumbaugh GW. Pharmacologic and alternative therapies for the horse with chronic laminitis.. Vet Clin North Am Equine Pract 1999;15:495–516.
                pubmed: 10472124
              32. Taylor PM, Pascoe PJ, Mama KR. Diagnosing and treating pain in the horse. Where are we today?. Vet Clin North Am Equine Pract 2002;18:1–19.
                pubmed: 12064173
              33. Teixeira Neto FJ, McDonell WN, Black WD. Effects of glycopyrrolate on cardiorespiratory function in horses anesthetized with halothane and xylazine.. Am J Vet Res 2004;65:456–463.
                pubmed: 15077688
              34. Terry RL, McDonnell SM, Van Eps AW. Pharmacokinetic profile and behavioral effects of gabapentin in the horse.. J Vet Pharmacol Ther 2010;33:485–494.
                pubmed: 20840393
              35. Tokuyama S, Nakamoto K. Unsaturated Fatty acids and pain.. Biol Pharm Bull 2011;34:1174–1178.
                pubmed: 21804202
              36. Tsai HJ, Hwang SH, Morisseau C. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.. Eur J Pharm Sci 2010;40:222–238.
                pmc: PMC3285443pubmed: 20359531
              37. Ulu A, Appt S, Morisseau C. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.. Br J Pharmacol 2011.
                pmc: PMC3372725pubmed: 21880036
              38. Vale ML, Benevides VM, Sachs D. Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain.. Br J Pharmacol 2004;143:833–844.
                pmc: PMC1575939pubmed: 15520047
              39. Vinuela-Fernandez I, Jones E, Chase-Topping ME. Comparison of subjective scoring systems used to evaluate equine laminitis.. Vet J 2011;188:171–177.
                pubmed: 20541956
              40. Wagner K, Inceoglu B, Gill SS. Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.. J Agric Food Chem 2011a;59:2816–2824.
                pmc: PMC3483885pubmed: 20958046
              41. Wagner K, Inceoglu B, Hammock BD. Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.. Prostaglandins Other Lipid Mediat 2011b;96:76–83.
                pmc: PMC3215909pubmed: 21854866
              42. Yu Z, Xu F, Huse LM. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.. Circ Res 2000;87:992–998.
                pubmed: 11090543

              Citations

              This article has been cited 34 times.
              1. Schmidt WK, Cortés-Puch I, McReynolds CB, Croston GE, Hwang SH, Yang J, Pedersen TL, Wagner KM, Pham TT, Hunt T, Hammock BD. Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers. Clin Transl Sci 2024 Sep;17(9):e70033.
                doi: 10.1111/cts.70033pubmed: 39300734google scholar: lookup
              2. McReynolds C, Hammock B, Morisseau C. Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression. Pharmacol Ther 2023 Aug;248:108454.
                doi: 10.1016/j.pharmthera.2023.108454pubmed: 37268114google scholar: lookup
              3. Wang W, Wang Y, Yang J, Wagner KM, Hwang SH, Cheng J, Singh N, Edwards P, Morisseau C, Zhang G, Panigrahy D, Hammock BD. Aflatoxin B(1) exposure disrupts the intestinal immune function via a soluble epoxide hydrolase-mediated manner. Ecotoxicol Environ Saf 2023 Jan 1;249:114417.
                doi: 10.1016/j.ecoenv.2022.114417pubmed: 36525946google scholar: lookup
              4. Ulu A, Velazquez JV, Burr A, Sveiven SN, Yang J, Bravo C, Hammock BD, Nordgren TM. Sex-Specific Differences in Resolution of Airway Inflammation in Fat-1 Transgenic Mice Following Repetitive Agricultural Dust Exposure. Front Pharmacol 2021;12:785193.
                doi: 10.3389/fphar.2021.785193pubmed: 35095496google scholar: lookup
              5. Tucker L, Trumble TN, Groschen D, Dobbs E, Baldo CF, Wendt-Hornickle E, Guedes AGP. Targeting Soluble Epoxide Hydrolase and Cyclooxygenases Enhance Joint Pain Control, Stimulate Collagen Synthesis, and Protect Chondrocytes From Cytokine-Induced Apoptosis. Front Vet Sci 2021;8:685824.
                doi: 10.3389/fvets.2021.685824pubmed: 34422942google scholar: lookup
              6. Iadarola MJ, Brown DC, Nahama A, Sapio MR, Mannes AJ. Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials. Front Pharmacol 2021;12:705743.
                doi: 10.3389/fphar.2021.705743pubmed: 34421597google scholar: lookup
              7. Mavangira V, Kuhn MJ, Abuelo A, Morisseau C, Hammock BD, Sordillo LM. Activity of sEH and Oxidant Status during Systemic Bovine Coliform Mastitis. Antioxidants (Basel) 2021 May 20;10(5).
                doi: 10.3390/antiox10050812pubmed: 34065244google scholar: lookup
              8. Hammock BD, McReynolds CB, Wagner K, Buckpitt A, Cortes-Puch I, Croston G, Lee KSS, Yang J, Schmidt WK, Hwang SH. Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative. J Med Chem 2021 Feb 25;64(4):1856-1872.
                doi: 10.1021/acs.jmedchem.0c01886pubmed: 33550801google scholar: lookup
              9. Wang Y, Wagner KM, Morisseau C, Hammock BD. Inhibition of the Soluble Epoxide Hydrolase as an Analgesic Strategy: A Review of Preclinical Evidence. J Pain Res 2021;14:61-72.
                doi: 10.2147/JPR.S241893pubmed: 33488116google scholar: lookup
              10. Lee KSS, Ng JC, Yang J, Hwang SH, Morisseau C, Wagner K, Hammock BD. Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain. Bioorg Med Chem 2020 Nov 15;28(22):115735.
                doi: 10.1016/j.bmc.2020.115735pubmed: 33007552google scholar: lookup
              11. Shihadih DS, Harris TR, Kodani SD, Hwang SH, Lee KSS, Mavangira V, Hamamoto B, Guedes A, Hammock BD, Morisseau C. Selection of Potent Inhibitors of Soluble Epoxide Hydrolase for Usage in Veterinary Medicine. Front Vet Sci 2020;7:580.
                doi: 10.3389/fvets.2020.00580pubmed: 33005645google scholar: lookup
              12. Park B, Corson TW. Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future. Front Pharmacol 2019;10:95.
                doi: 10.3389/fphar.2019.00095pubmed: 30792659google scholar: lookup
              13. de Oliveira GS, Adriani PP, Ribeiro JA, Morisseau C, Hammock BD, Dias MVB, Chambergo FS. The molecular structure of an epoxide hydrolase from Trichoderma reesei in complex with urea or amide-based inhibitors. Int J Biol Macromol 2019 May 15;129:653-658.
                doi: 10.1016/j.ijbiomac.2019.02.070pubmed: 30771398google scholar: lookup
              14. de Oliveira GS, Adriani PP, Wu H, Morisseau C, Hammock BD, Chambergo FS. Substrate and inhibitor selectivity, and biological activity of an epoxide hydrolase from Trichoderma reesei. Mol Biol Rep 2019 Feb;46(1):371-379.
                doi: 10.1007/s11033-018-4481-4pubmed: 30426381google scholar: lookup
              15. Kodani SD, Bhakta S, Hwang SH, Pakhomova S, Newcomer ME, Morisseau C, Hammock BD. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. Bioorg Med Chem Lett 2018 Feb 15;28(4):762-768.
                doi: 10.1016/j.bmcl.2018.01.003pubmed: 29366648google scholar: lookup
              16. Guedes AGP, Aristizabal F, Sole A, Adedeji A, Brosnan R, Knych H, Yang J, Hwang SH, Morisseau C, Hammock BD. Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis. J Vet Pharmacol Ther 2018 Apr;41(2):230-238.
                doi: 10.1111/jvp.12463pubmed: 29067696google scholar: lookup
              17. Wagner KM, McReynolds CB, Schmidt WK, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther 2017 Dec;180:62-76.
                doi: 10.1016/j.pharmthera.2017.06.006pubmed: 28642117google scholar: lookup
              18. Kitamura S, Morisseau C, Harris TR, Inceoglu B, Hammock BD. Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales. PLoS One 2017;12(5):e0176571.
                doi: 10.1371/journal.pone.0176571pubmed: 28472063google scholar: lookup
              19. McLellan GJ, Aktas Z, Hennes-Beean E, Kolb AW, Larsen IV, Schmitz EJ, Clausius HR, Yang J, Hwang SH, Morisseau C, Inceoglu B, Hammock BD, Brandt CR. Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit. J Ocul Biol 2016 Jan;4(1).
                doi: 10.13188/2334-2838.1000024pubmed: 28066796google scholar: lookup
              20. Guedes A, Galuppo L, Hood D, Hwang SH, Morisseau C, Hammock BD. Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis. Equine Vet J 2017 May;49(3):345-351.
                doi: 10.1111/evj.12603pubmed: 27338788google scholar: lookup
              21. Liu JY, Tsai HJ, Morisseau C, Lango J, Hwang SH, Watanabe T, Kim IH, Hammock BD. In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Biochem Pharmacol 2015 Dec 15;98(4):718-31.
                doi: 10.1016/j.bcp.2015.10.013pubmed: 26494425google scholar: lookup
              22. Inceoglu B, Bettaieb A, Trindade da Silva CA, Lee KS, Haj FG, Hammock BD. Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain. Proc Natl Acad Sci U S A 2015 Jul 21;112(29):9082-7.
                doi: 10.1073/pnas.1510137112pubmed: 26150506google scholar: lookup
              23. Sasso O, Wagner K, Morisseau C, Inceoglu B, Hammock BD, Piomelli D. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. Pharmacol Res 2015 Jul;97:7-15.
                doi: 10.1016/j.phrs.2015.04.001pubmed: 25882247google scholar: lookup
              24. Kodani SD, Hammock BD. The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain. Drug Metab Dispos 2015 May;43(5):788-802.
                doi: 10.1124/dmd.115.063339pubmed: 25762541google scholar: lookup
              25. Kitamura S, Morisseau C, Inceoglu B, Kamita SG, De Nicola GR, Nyegue M, Hammock BD. Potent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: synthesis, quantification, and measurement of biological activities in vitro and in vivo. PLoS One 2015;10(2):e0117438.
                doi: 10.1371/journal.pone.0117438pubmed: 25659109google scholar: lookup
              26. Shihadih DS, Harris TR, Yang J, Merzlikin O, Lee KS, Hammock BD, Morisseau C. Identification of potent inhibitors of the chicken soluble epoxide hydrolase. Bioorg Med Chem Lett 2015 Jan 15;25(2):276-9.
                doi: 10.1016/j.bmcl.2014.11.053pubmed: 25479771google scholar: lookup
              27. Piomelli D, Hohmann AG, Seybold V, Hammock BD. A lipid gate for the peripheral control of pain. J Neurosci 2014 Nov 12;34(46):15184-91.
                doi: 10.1523/JNEUROSCI.3475-14.2014pubmed: 25392487google scholar: lookup
              28. Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol 2015 Jan 15;308(2):F131-9.
                doi: 10.1152/ajprenal.00531.2014pubmed: 25377915google scholar: lookup
              29. Wagner K, Vito S, Inceoglu B, Hammock BD. The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling. Prostaglandins Other Lipid Mediat 2014 Oct;113-115:2-12.
                doi: 10.1016/j.prostaglandins.2014.09.001pubmed: 25240260google scholar: lookup
              30. Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem 2014 Aug 28;57(16):7016-30.
                doi: 10.1021/jm500694ppubmed: 25079952google scholar: lookup
              31. Wagner K, Yang J, Inceoglu B, Hammock BD. Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. J Pain 2014 Sep;15(9):907-14.
                doi: 10.1016/j.jpain.2014.05.008pubmed: 24924124google scholar: lookup
              32. Shrestha A, Krishnamurthy PT, Thomas P, Hammock BD, Hwang SH. Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats. J Pharm Pharmacol 2014 Sep;66(9):1251-8.
                doi: 10.1111/jphp.12251pubmed: 24697323google scholar: lookup
              33. Inceoglu B, Zolkowska D, Yoo HJ, Wagner KM, Yang J, Hackett E, Hwang SH, Lee KS, Rogawski MA, Morisseau C, Hammock BD. Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures. PLoS One 2013;8(12):e80922.
                doi: 10.1371/journal.pone.0080922pubmed: 24349022google scholar: lookup
              34. Zhang G, Kodani S, Hammock BD. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res 2014 Jan;53:108-23.
                doi: 10.1016/j.plipres.2013.11.003pubmed: 24345640google scholar: lookup
              Subscribe to our newsletter
              Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.